
Trump Administration Executive Order (EO) Tracker
Companies in all industries are increasingly using influencers and their large reach to market their products or services on social networks such as Instagram. For a long time there has been discussion in this context about the legal consequences of these marketing activities, in particular whether they should be subject to labelling requirements for advertising. Now the German Federal Court of Justice („BGH“) has finally dealt with this issue, after there were different directions of decision by courts. Further changes in the legislation entered into force on 28 May 2022. Influencers and companies engaging with influencers should keep an eye on this.
In September 2021, the BGH has for the first time decided on influencer marketing and issued three rulings of fundamental importance for the question of whether posts on Instagram must be labeled as advertising. The overall conclusion was that a label obligation for "third-party advertising" of influencers shall generally only exist if they have received a consideration for their contributions and the intended third-party promotion is not already evident from the circumstances.
In January 2022, the BGH supplemented its case law with two further decisions (I ZR 9/21, I ZR 35/21) which concerned with provision of goods and service free of charge. The most recent decision on influencer marketing comes from the Higher Regional Court of Frankfurt am Main (dated 19 May 2022 – 6 U 56/21)., which followed the BGH case law. The court ruled that an influencer who published posts linking to various e-books and highlighting the exceptionally high discount price of the e-books was considered unfair advertising – regardless of the fact that the influencer did not receive any further remuneration.
While the court decisions already provide for some legal certainty for influencers and companies using influencers, the German legislator has in the meantime also taken action to address this issue. The Act to Strengthen Consumer Protection in Competition and Trade Law (Gesetz zur Stärkung des Verbraucherschutzes im Wettbewerbs- und Gewerberecht) entered into force on 28 May 2022 and amended the German Law against unfair competition (Gesetz gegen den unlauteren Wettbewerb („UWG“)).
Similar to the arguments provided by the BGH, with respect to the existence of a labelling obligation, the new provisions distinguish primarily based on the fact if a consideration is received for the promotional content or not. In accordance with the recent changes to the UWG, a person also acts unfairly if he/she fails to disclose the commercial purpose of a commercial act, unless this purpose is immediately apparent from the circumstances, and the failure to disclose is likely to cause the consumer or other market participant to take a decision that he would not otherwise have taken. A commercial purpose shall not exist in the case of an action in favour of another company if the acting person does not receive any consideration or does not allow himself/herself to be promised any consideration.
There is a variety of further legal issues that may arise in the context of influencer marketing. Below we listed those issues that may typically become relevant:
Influencer marketing has recently become a more prominent topic also in the life sciences industry. However, the heavily regulated environment requires that further legal aspects be considered in addition to the above. Foremost, it is not allowed to promote prescription only (Rx) medicines to the general public, i.e., outside the closed medical community. As access to social media channels can usually not be restricted to a specific audience (e.g., HCPs), permissible activities by influencers are limited to corporate promotion or disease awareness campaigns. This may be different for medicinal products not subject to prescription (pharmacy-only / OTC products), where no prohibition of product promotion towards the general public applies. Nevertheless, further legal requirements must be considered: E.g., for OTC medicines, advertising by way of celebrity endorsement is prohibited pursuant to Sec. 11 (1) No. 2 of the German Healthcare Advertising Act (HCAA). At least influencers with a significant number of followers (so called macro influencers; from 50-100k followers) will be considered celebrities and, therefore, cannot promote OTC medicines. Arguably, the same applies for micro-influencers, who have less followers but often a very specific target audience and higher engagement rates. The intention of the law is to prevent that patients use medicinal products due to the mere recommendation or endorsement by a well-known person – rather than due to a medical need. Therefore, also micro-influencers can arguably be considered „celebrities within their specific audience“, thus falling under Sec. 11 (1) No. 2 HCAA. Still, in the absence of case law there are certainly also arguments for micro-influencers not qualifying as „celebrities“. However, even then Sec. 11 (1) No. 11 HCAA prohibits promotion with testimonials when they are improper, repulsive or misleading.
Besides advertising laws, influencer marketing also touches upon other legal topics. E.g., in life sciences unwanted/side effects which are reported by patients/physicians may have to be followed up and monitored. Whether the mere corporate promotion or disease awareness communication made by an influencer already triggers the requirement for a pharmaceutical company to monitor user generated content under the influencer’s posts for adverse event reports has not yet been decided – but would rather be a somewhat too strict interpretation.
Authored by Nadine Otz, Susanne Schuster, and Benjamin Goehl.